Ixekizumab Prefilled Syringe

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Uveitis, Posterior

Conditions

Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis

Trial Timeline

Jun 1, 2022 → Dec 30, 2024

NCT ID

NCT06085079

About Ixekizumab Prefilled Syringe

Ixekizumab Prefilled Syringe is a approved stage product being developed by Eli Lilly for Uveitis, Posterior. The current trial status is unknown. This product is registered under clinical trial identifier NCT06085079. Target conditions include Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate.

What happened to similar drugs?

2 of 20 similar drugs in Uveitis, Posterior were approved

Approved (2) Terminated (9) Active (9)

✅AdalimumabAbbVieApproved

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06085079	Approved	UNKNOWN	Jun 1, 2022	Dec 30, 2024	Uveitis, Posterior

Competing Products

20 competing products in Uveitis, Posterior

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32